HSK7653
Phase 3Small molecule
Haisco Pharmaceutical Group Co., Ltd.HSK7653 is one of 81 small molecule programs targeting Impaired glucose tolerance. It is currently in Phase 3.
3
Indications
10
Total Trials
0
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
HSK7653
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes2 trials
Type 2 Diabetes Mellitus1 trial
2 more indications
Renal Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HSK7653. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details